Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by prophetoffactzon Sep 12, 2024 6:35pm
16 Views
Post# 36221300

RE:Those suffering osteoarthritis, diabetes, and heart disease

RE:Those suffering osteoarthritis, diabetes, and heart diseaseAvenanthramide could affect so many conditions many of which tend to be common to the same patients.

----

Avenanthramides, unique phenolic compounds found in oats, have been shown to have a significant impact on glucose metabolism and insulin sensitivity. Research indicates that avenanthramides can inhibit glucose absorption in the intestines, which may contribute to their antidiabetic properties. Specifically, studies have demonstrated that the presence of avenanthramides reduces glucose uptake in intestinal models, suggesting a mechanism by which they could help manage blood sugar levels and improve insulin responses.Moreover, the consumption of oats, which are rich in avenanthramides, has been associated with lower postprandial (after meal) insulin responses. Meta-analyses have shown that regular oat intake can significantly decrease fasting insulin concentrations and improve insulin sensitivity, particularly in individuals with type 2 diabetes. This effect is partly attributed to the soluble fiber, beta-glucan, present in oats, which enhances the viscosity of intestinal contents, slows carbohydrate digestion, and promotes satiety.In summary, avenanthramides appear to positively affect insulin sensitivity and glucose metabolism, making them a beneficial component of diets aimed at managing blood sugar levels and enhancing overall metabolic health.
<< Previous
Bullboard Posts
Next >>